Appendix A

1. (First Time Amended) A method for the treatment of asthma comprising administering to a mammal suffering from asthma a composition comprising a soluble fibronectin polypeptide.

2. (First Time Amended) The method of Claim 1, wherein the composition is administered intravenously.

3. (First Time Amended) The method of Claim 1, wherein the composition is administered in the form of an aerosol by inhalation.

6. (First Time Amended) The method of Claim 1, wherein the composition is administered at a dosage so as to provide from 0.05 to 5.0 mg/kg of fibronectin polypeptide, based on the weight of the asthma sufferer.

7. (First Time Amended) The method of Claim 6, wherein the composition is administered to the mammal at a dosage so as to provide 0.5 to 2.0 mg/kg of fibronectin polypeptide, based on the weight of the asthma sufferer.

9. (First Time Amended) The method of Claim 1, wherein the composition is administered to the mammal prior to exposure to an allergen to which the asthma sufferer is hypersensitive.

10. (Reiterated) The method of Claim 1, wherein the mammal is a human.

11. (First Time Amended) The method of Claim 1, wherein the composition is administered to the mammal after exposure to an allergen to which said mammal is hypersensitive.

12. (First time amended) A method for the treatment of asthma comprising administering to a mammal suffering from allergic asthma a soluble fibronectin polypeptide capable of binding to the α_4 subunit of VLA-4, in an amount effective to provide inhibition of late phase response to an allergen to which the sufferer is hypersensitive or to provide decreased airway hypersensitivity in said mammal following allergen challenge.

13. (First time amended) The method of Claim 12, wherein the soluble fibronectin polypeptide comprises an EILDV motif.

17. (First time amended) The method of Claim 12, wherein the composition is administered at a dosage so as to provide from 0.05 to 5.0 mg/kg of polypeptide, based on the weight of the asthma sufferer.

18. (First time amended) The method of Claim 17, wherein the composition is administered at a dosage so as to provide 1.0-2.0 mg/kg of polypeptide, based on the weight of the asthma sufferer.

26. (New) The method according to Claim 1, wherein the soluble fibronectin polypeptide comprises an EILDV motif.

27. (New) The method according to Claim 1, wherein the soluble fibronectin polypeptide comprises an alternatively spliced non-type III connecting segment.

28. (New) The method of Claim 12, wherein the soluble fibronectin polypeptide comprises an alternatively spliced non-type III connecting segment.

29. (New) The method of Claim 12, wherein the mammal is a human.

30. (New) The method of Claim 1, wherein the composition is administered to the mammal at the time or immediately after allergen exposure.

31. (New) The method of Claim 1, wherein the composition is administered to the mammal between the early phase and late phase response.

32. (New) The method of Claim 12, wherein the composition is administered to the mammal prior to exposure to an allergen to which the asthma sufferer is hypersensitive.

33. (New) The method of Claim 12, wherein the composition is administered to the mammal at the time or immediately after allergen exposure.

34. (New) The method of Claim 12, wherein the composition is administered to the mammal between the early phase and late phase response.

35. (New) The method of Claim 12, wherein the composition is administered to the mammal after allergen exposure.

36. (New) The method of Claim 12, wherein the composition is administered intravenously.

37. (New) The method of Claim 12, wherein the composition is administered in the form of an aerosol by inhalation.